WuXi Biologics (Cayman) Inc.

WXIBF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income$2,339$3,335$1,499$1,700
Dep. & Amort.$854$653$784$585
Deferred Tax$0$0$0$0
Stock-Based Comp.$469$525$690$637
Change in WC$0-$801$0-$448
Other Non-Cash-$1,856$202-$1,671-$140
Operating Cash Flow$1,807$3,915$1,302$2,334
Investing Activities
PP&E Inv.-$1,900-$2,062-$1,867-$2,023
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$11,429$0-$7,542
Inv. Sales/Matur.$0$10,893$0$7,819
Other Inv. Act.$1,362-$961$1,485$131
Investing Cash Flow-$538-$3,559-$383-$1,614
Financing Activities
Debt Repay.$2$490-$70-$409
Stock Issued$0$19$0$13
Stock Repurch.-$1,032-$532-$1,234-$458
Dividends Paid$0$0$0$0
Other Fin. Act.-$56-$1,253-$172$3,004
Financing Cash Flow-$1,086-$1,275-$1,476$2,149
Forex Effect-$23$44$40-$63
Net Chg. in Cash$8,439$8,537-$258$3,275
Supplemental Information
Beg. Cash$0-$258$0$6,395
End Cash$8,439$8,279-$258$9,670
Free Cash Flow-$94$1,853-$565$219
WuXi Biologics (Cayman) Inc. (WXIBF) Financial Statements & Key Stats | AlphaPilot